MCID: DBT084
MIFTS: 49

Diabetes Mellitus, Ketosis-Prone

Categories: Genetic diseases, Metabolic diseases

Aliases & Classifications for Diabetes Mellitus, Ketosis-Prone

MalaCards integrated aliases for Diabetes Mellitus, Ketosis-Prone:

Name: Diabetes Mellitus, Ketosis-Prone 54 12 71 29 13
Diabetic Ketoacidosis 12 52 42 14 69
Diabetes Mellitus, Insulin-Dependent 69
Ketosis-Prone Diabetes Mellitus 12
Kpd 71

Characteristics:

OMIM:

54
Miscellaneous:
near-normoglycemic remission for period of months to years without insulin treatment
hla class ii alleles specify ketosis-prone diabetes (kpd) subgroup

Inheritance:
autosomal dominant


HPO:

32
diabetes mellitus, ketosis-prone:
Inheritance autosomal dominant inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 54 612227
Disease Ontology 12 DOID:1837
ICD9CM 35 250.1
NCIt 47 C50530
MedGen 40 C0743110
UMLS 69 C0011880

Summaries for Diabetes Mellitus, Ketosis-Prone

OMIM : 54
In addition to classic type 1 (see 222100) and type 2 (see 125853) diabetes mellitus, atypical presentations are seen, particularly in populations of African ancestry. Ketosis-prone diabetes, the most common atypical form, is characterized by an acute initial presentation with severe hyperglycemia and ketosis, as seen in classic type 1 diabetes, but after initiation of insulin therapy, prolonged remission is often possible with cessation of insulin therapy and maintenance of appropriate metabolic control. Metabolic studies show a markedly blunted insulin secretory response to glucose, partially reversible with the improvement of blood glucose control. Variable levels of insulin resistance are observed, especially in obese patients. Pancreatic beta-cell autoimmunity is a rare finding, and association with type 1 susceptibility HLA alleles is variable (Sobngwi et al., 2002). (612227)

MalaCards based summary : Diabetes Mellitus, Ketosis-Prone, also known as diabetic ketoacidosis, is related to cerebritis and monocarboxylate transporter 1 deficiency, and has symptoms including diabetes mellitus, insulin resistance and beta-cell dysfunction. An important gene associated with Diabetes Mellitus, Ketosis-Prone is PAX4 (Paired Box 4), and among its related pathways/superpathways are Allograft rejection and Glucose / Energy Metabolism. The drugs Insulin Detemir and Insulin Glargine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, kidney and testes, and related phenotype is homeostasis/metabolism.

UniProtKB/Swiss-Prot : 71 Diabetes mellitus, ketosis-prone: An atypical form of diabetes mellitus characterized by an acute initial presentation with severe hyperglycemia and ketosis, as seen in classic type 1 diabetes, but after initiation of insulin therapy, prolonged remission is often possible with cessation of insulin therapy and maintenance of appropriate metabolic control. Metabolic studies show a markedly blunted insulin secretory response to glucose, partially reversible with the improvement of blood glucose control. Variable levels of insulin resistance are observed, especially in obese patients. Pancreatic beta-cell autoimmunity is a rare finding.

Related Diseases for Diabetes Mellitus, Ketosis-Prone

Diseases related to Diabetes Mellitus, Ketosis-Prone via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
id Related Disease Score Top Affiliating Genes
1 cerebritis 10.4
2 monocarboxylate transporter 1 deficiency 10.3 GAD1 INS
3 dyskinetic cerebral palsy 10.3 GAD1 GAD2
4 celiac disease 3 10.3 CTLA4 INS
5 linear lichen planus 10.3 GAD1 GAD2
6 hyperphosphatasia with mental retardation syndrome 3 10.3 CTLA4 INS
7 pathologic nystagmus 10.3 GAD1 PIK3C2A
8 neuropathy, hereditary sensory and autonomic, type ic 10.3 CTLA4 INS
9 pancreatitis 10.2
10 hyperlipoproteinemia type iv 10.2 GAD1 INS
11 satoyoshi syndrome 10.1 GAD1 GAD2 INS
12 metabolic acidosis 10.1
13 hypertrichosis 10.1 GAD2 INS SLC5A2
14 survival motor neuron spinal muscular atrophy 10.1 GAD2 INS SLC5A2
15 atrial tachyarrhythmia with short pr interval 10.1 GAD1 GAD2 INS
16 phaeohyphomycosis 10.1 GAD1 GAD2 INS
17 acute pancreatitis 10.1
18 hyperglycemia 10.1
19 neurogenic arthropathy 10.1 INS SLC5A2
20 acromegaly 10.0
21 congenital heart defects, nonsyndromic, 2 10.0 CTLA4 INS
22 hypertriglyceridemia 10.0
23 hypokalemic periodic paralysis, type 1 10.0 BRD4 INS
24 breast cancer 10.0 CTLA4 GAD2 INS
25 hypoglycemia 10.0
26 hypokalemia 10.0
27 pseudohypoparathyroidism 10.0 CTLA4 GAD2 INS
28 hypophosphatemia 10.0
29 thyroiditis 9.9
30 thrombosis 9.9
31 hepatitis 9.9
32 neuronitis 9.9
33 lactic acidosis 9.9
34 influenza 9.9
35 obesity 9.9
36 methylmalonic acidemia 9.9
37 brain edema 9.9
38 chondroma 9.9 INS SLC5A2
39 trochlear nerve neoplasm 9.9 BRD4 RHNO1
40 zygomycosis 9.8
41 isovaleric acidemia 9.8
42 encephalopathy 9.8
43 pheochromocytoma 9.8
44 extrapontine myelinolysis 9.8
45 somatostatinoma 9.8
46 respiratory failure 9.8
47 gigantism 9.8
48 hypolipoproteinemia 9.8 BRD4 RHNO1
49 pyelonephritis 9.7
50 acanthosis nigricans 9.7

Comorbidity relations with Diabetes Mellitus, Ketosis-Prone via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Heart Disease Hypertension, Essential
Ischemic Heart Disease

Graphical network of the top 20 diseases related to Diabetes Mellitus, Ketosis-Prone:



Diseases related to Diabetes Mellitus, Ketosis-Prone

Symptoms & Phenotypes for Diabetes Mellitus, Ketosis-Prone

Symptoms via clinical synopsis from OMIM:

54

Immunology:
autoimmunity to pancreatic beta cells (rare)

Abdomen- Pancreas:
beta-cell dysfunction of varying degrees

Metabolic Features:
insulin resistance, variable
ketoacidosis


Clinical features from OMIM:

612227

Human phenotypes related to Diabetes Mellitus, Ketosis-Prone:

32
id Description HPO Frequency HPO Source Accession
1 diabetes mellitus 32 HP:0000819
2 insulin resistance 32 HP:0000855
3 beta-cell dysfunction 32 HP:0006279
4 ketoacidosis 32 HP:0001993
5 autoimmunity 32 HP:0002960

UMLS symptoms related to Diabetes Mellitus, Ketosis-Prone:


polyuria, polydipsia

MGI Mouse Phenotypes related to Diabetes Mellitus, Ketosis-Prone:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.23 ACACA CTLA4 GAD1 GAD2 INS PAX4

Drugs & Therapeutics for Diabetes Mellitus, Ketosis-Prone

Drugs for Diabetes Mellitus, Ketosis-Prone (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 572)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1 169148-63-4 5311023
2
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
3
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
4
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 204656-20-2 44147092
5
Pancrelipase Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53608-75-6
6
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2 174722-31-7 10201696
7
Febuxostat Approved Phase 4 144060-53-7 134018
8
Nitric Oxide Approved Phase 4 10102-43-9 145068
9
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
10
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
11
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 133107-64-9
12
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
13
Diazoxide Approved Phase 4 364-98-7 3019
14
Glyburide Approved Phase 4,Phase 2,Phase 3 10238-21-8 3488
15
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
17
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 141758-74-9 15991534
18
Pramlintide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 151126-32-8
19
Metformin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 657-24-9 14219 4091
20
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2 274901-16-5 6918537
21
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
22
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
23
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
24
Adenosine Approved, Investigational Phase 4 58-61-7 60961
25
Regadenoson Approved Phase 4 313348-27-5 219024
26
Ethanol Approved Phase 4,Phase 2,Phase 1,Early Phase 1 64-17-5 702
27
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
28
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
29
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
30
Norepinephrine Approved Phase 4 51-41-2 439260
31
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
32
Saxagliptin Approved Phase 4,Phase 3,Phase 2 361442-04-8 11243969
33
Allopurinol Approved Phase 4,Phase 3 315-30-0 2094
34
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
35
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2 216503-57-0
36
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
37
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
38
Gliclazide Approved Phase 4 21187-98-4 3475
39
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
40
Diphenhydramine Approved Phase 4 58-73-1, 147-24-0 3100
41
Promethazine Approved Phase 4 60-87-7 4927
42
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
43
Inulin Approved, Nutraceutical Phase 4,Early Phase 1 9005-80-5 24763
44
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
45
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
46
Vitamin C Approved, Nutraceutical Phase 4,Phase 1 50-81-7 5785 54670067
47
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 67-97-0 6221 10883523 5280795
48 Tocopherol Approved, Nutraceutical Phase 4,Phase 3,Phase 1
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1 59-02-9 14985
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 11103-57-4, 68-26-8 445354

Interventional clinical trials:

(show top 50) (show all 2121)

id Name Status NCT ID Phase Drugs
1 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
2 52 Week Trial of Liraglutide in Type 1 Diabetes Unknown status NCT01787916 Phase 4 Liraglutide
3 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
4 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
5 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4 Glucagon
6 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4 Febuxostat
7 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) Unknown status NCT01848990 Phase 4 Commercial Hylenex® recombinant (hyaluronidase human injection);Precommercial Hylenex recombinant (hyaluronidase human injection);Insulin lispro;Insulin aspart;Insulin glulisine
8 Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis Unknown status NCT01271517 Phase 4 NPH insulin;Glargine;Detemir
9 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
10 Use of Diazoxide in Acute Hypoglycaemia Unknown status NCT01488136 Phase 4 Diazoxide;Placebo
11 Dapagliflozin in Type 1 Diabetes Unknown status NCT02211742 Phase 4 Dapagliflozin
12 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
13 Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 DM Unknown status NCT01338922 Phase 4
14 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4 Glibenclamide
15 Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy Unknown status NCT00328302 Phase 4 Candesartan;Placebo
16 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
17 Obtain a Good Blood Glucose Control With the Paradigm Real Time System Unknown status NCT00441129 Phase 4
18 GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients Unknown status NCT01592279 Phase 4 liraglutide;Insulin injections
19 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
20 Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes Completed NCT00315952 Phase 4 Exubera
21 Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus Completed NCT01868594 Phase 4 Subetta;Placebo
22 Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes Completed NCT00978796 Phase 4 Sitagliptin;Sugar Pill
23 Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus Completed NCT01235819 Phase 4 Insulin;Sitagliptin;Exenatide
24 Efficacy of Diazoxide in Type 1 Diabetes Completed NCT00131755 Phase 4 diazoxide
25 Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children Completed NCT00069615 Phase 4
26 Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus Completed NCT00442767 Phase 4 Pramlintide acetate
27 Liraglutide in Type 1 Diabetes Completed NCT01612468 Phase 4 Liraglutide;Placebo
28 Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes Completed NCT00284232 Phase 4 Insulin dosing based on SMBG chart and education
29 Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet Completed NCT00118937 Phase 4 Metformin;Placebo.;Placebo.
30 A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes Completed NCT01718093 Phase 4 Sitagliptin;Metformin;Sitagliptin + Metformin
31 Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes Completed NCT01397513 Phase 4 Aspirin
32 Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes Completed NCT01390480 Phase 4 Cholecalciferol
33 Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes Completed NCT00276393 Phase 4 Basal insulin
34 The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 Completed NCT01277913 Phase 4 Vitamin D3;Vitamin D3
35 Sitagliptin Dose Determination Study Completed NCT01530178 Phase 4 Sitagliptin
36 Prevention of Severe Hypoglycemia in Type 1 Diabetes Completed NCT00360984 Phase 4 insulin glargine
37 Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus Completed NCT01678235 Phase 4 Insulin glulisine;Insulin aspart
38 Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study Completed NCT01825382 Phase 4
39 Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Completed NCT00964574 Phase 4 INSULIN GLULISINE (HMR1964);INSULIN GLARGINE
40 A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus Completed NCT02688933 Phase 4 Insulin glargine (U300) HOE901;Insulin glargine HOE901;Insulin glulisine HMR1964;Insulin aspart;Insulin lispro
41 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment Completed NCT01099618 Phase 4 metformin;placebo;Sitagliptin
42 Human Insulin NPH and Insulin Aspart in Type 1 Diabetes Completed NCT00597233 Phase 4 insulin aspart;soluble human insulin;insulin NPH
43 Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes Completed NCT01467141 Phase 4 insulin aspart;human insulin;isophane human insulin
44 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed NCT01269047 Phase 4 Pramlintide;Exenatide;Insulin
45 Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes Completed NCT00571935 Phase 4 insulin aspart;soluble human insulin
46 Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus Completed NCT00898534 Phase 4
47 Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes Completed NCT00117780 Phase 4 insulin detemir;insulin aspart
48 The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus Completed NCT00145379 Phase 4 Tablet Metformin 500 mg;Placebo
49 The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins Completed NCT00313742 Phase 4 insulin detemir;insulin glargine;insulin NPH
50 Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) Completed NCT00390728 Phase 4 Insulin Glargine

Search NIH Clinical Center for Diabetes Mellitus, Ketosis-Prone

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: diabetic ketoacidosis

Genetic Tests for Diabetes Mellitus, Ketosis-Prone

Genetic tests related to Diabetes Mellitus, Ketosis-Prone:

id Genetic test Affiliating Genes
1 Diabetes Mellitus, Ketosis-Prone 29

Anatomical Context for Diabetes Mellitus, Ketosis-Prone

MalaCards organs/tissues related to Diabetes Mellitus, Ketosis-Prone:

39
Pancreas, Kidney, Testes, Bone, Brain, Pancreatic Islet, Endothelial

Publications for Diabetes Mellitus, Ketosis-Prone

Variations for Diabetes Mellitus, Ketosis-Prone

UniProtKB/Swiss-Prot genetic disease variations for Diabetes Mellitus, Ketosis-Prone:

71
id Symbol AA change Variation ID SNP ID
1 PAX4 p.Arg45Trp VAR_054880
2 PAX4 p.Arg141Trp VAR_054882 rs2233578

Expression for Diabetes Mellitus, Ketosis-Prone

Search GEO for disease gene expression data for Diabetes Mellitus, Ketosis-Prone.

Pathways for Diabetes Mellitus, Ketosis-Prone

GO Terms for Diabetes Mellitus, Ketosis-Prone

Cellular components related to Diabetes Mellitus, Ketosis-Prone according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 inhibitory synapse GO:0060077 8.96 GAD1 GAD2
2 clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane GO:0061202 8.62 GAD1 GAD2

Biological processes related to Diabetes Mellitus, Ketosis-Prone according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.54 GAD1 GAD2 PAX4
2 neurotransmitter secretion GO:0007269 9.32 GAD1 GAD2
3 positive regulation of cell differentiation GO:0045597 9.26 INS PAX4
4 carboxylic acid metabolic process GO:0019752 9.16 GAD1 GAD2
5 neurotransmitter biosynthetic process GO:0042136 8.96 GAD1 GAD2
6 glutamate decarboxylation to succinate GO:0006540 8.62 GAD1 GAD2

Molecular functions related to Diabetes Mellitus, Ketosis-Prone according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 pyridoxal phosphate binding GO:0030170 9.26 GAD1 GAD2
2 carboxy-lyase activity GO:0016831 9.16 GAD1 GAD2
3 glutamate binding GO:0016595 8.96 GAD1 GAD2
4 glutamate decarboxylase activity GO:0004351 8.62 GAD1 GAD2

Sources for Diabetes Mellitus, Ketosis-Prone

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....